ERD

Force-tuned avidity of spike variant-ACE2 interactions viewed on the single-molecule level.

Project: MAD-CoV 2

Updated at: 31-03-2024

Show more information

Project acronym MAD-CoV 2

Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19.

Project: MAD-CoV 2

Updated at: 31-03-2024

Show more information

Project acronym MAD-CoV 2

A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo.

Project: MAD-CoV 2

Updated at: 31-03-2024

Show more information

Project acronym MAD-CoV 2

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebul...

Project: MAD-CoV 2

Updated at: 31-03-2024

Show more information

Project acronym MAD-CoV 2

Angiotensin-converting enzyme 2-at the heart of the COVID-19 pandemic

Project: MAD-CoV 2

Updated at: 31-03-2024

Show more information

Project acronym MAD-CoV 2

Protocol for SARS-CoV-2 infection of kidney organoids derived from human pluripotent stem cells

Project: MAD-CoV 2

Updated at: 31-12-2023

Show more information

Project acronym MAD-CoV 2

Assessing kidney development and disease using kidney organoids and CRISPR engineering

Project: MAD-CoV 2

Updated at: 31-12-2023

Show more information

Project acronym MAD-CoV 2

Communication and dissemination update

Project: MAD-CoV 2

Updated at: 31-12-2023

Show more information

Project acronym MAD-CoV 2

A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoi...

Project: MAD-CoV 2

Updated at: 31-07-2023

Show more information

Project acronym MAD-CoV 2

Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response

Project: MAD-CoV 2

Updated at: 31-07-2023

Show more information

Project acronym MAD-CoV 2

Updated version of Data Management Plan

Project: MAD-CoV 2

Updated at: 31-07-2023

Show more information

Project acronym MAD-CoV 2

Human recombinant soluble ACE2 in severe COVID-19

Project: MAD-CoV 2

Updated at: 31-07-2023

Show more information

Project acronym MAD-CoV 2

Consortium secured intranet

Project: MAD-CoV 2

Updated at: 31-07-2023

Show more information

Project acronym MAD-CoV 2

Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection

Project: MAD-CoV 2

Updated at: 31-07-2023

Show more information

Project acronym MAD-CoV 2

The Short- and Long-Range RNA-RNA Interactome of SARS-CoV-2

Project: MAD-CoV 2

Updated at: 31-07-2023

Show more information

Project acronym MAD-CoV 2

Identification of SARS-CoV-2–induced pathways reveals drug repurposing strategies

Project: MAD-CoV 2

Updated at: 31-07-2023

Show more information

Project acronym MAD-CoV 2

Project website and communication pack

Project: MAD-CoV 2

Updated at: 31-07-2023

Show more information

Project acronym MAD-CoV 2

Draft of Data Management Plan

Project: MAD-CoV 2

Updated at: 31-07-2023

Show more information

Project acronym MAD-CoV 2

Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor

Project: MAD-CoV 2

Updated at: 31-07-2023

Show more information

Project acronym MAD-CoV 2

Low Density Lipoprotein Receptor-Related Protein 1 (LRP1) is a host factor for RNA viruses including SARS-CoV-2

Project: MAD-CoV 2

Updated at: 31-07-2023

Show more information

Project acronym MAD-CoV 2

ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopa...

Project: MAD-CoV 2

Updated at: 31-07-2023

Show more information

Project acronym MAD-CoV 2

Identification of lectin receptors for conserved SARS-CoV-2 glycosylation sites

Project: MAD-CoV 2

Updated at: 31-07-2023

Show more information

Project acronym MAD-CoV 2

Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants

Project: MAD-CoV 2

Updated at: 31-07-2023

Show more information

Project acronym MAD-CoV 2

Periodic Reporting for period 2 - MAD-CoV 2 (Modern approaches for developing antivirals against SARS-CoV 2)

Project: MAD-CoV 2

Updated at: 04-03-2023

Show more information

Project acronym MAD-CoV 2

Resources

Selected filters:

Force-tuned avidity of spike variant-ACE2 interactions viewed on the single-molecule level.

Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19.

A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo.

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebul...

Angiotensin-converting enzyme 2-at the heart of the COVID-19 pandemic

Protocol for SARS-CoV-2 infection of kidney organoids derived from human pluripotent stem cells

Assessing kidney development and disease using kidney organoids and CRISPR engineering

Communication and dissemination update

A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoi...

Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response

Updated version of Data Management Plan

Human recombinant soluble ACE2 in severe COVID-19

Consortium secured intranet

Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection

The Short- and Long-Range RNA-RNA Interactome of SARS-CoV-2

Identification of SARS-CoV-2–induced pathways reveals drug repurposing strategies

Project website and communication pack

Draft of Data Management Plan

Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor

Low Density Lipoprotein Receptor-Related Protein 1 (LRP1) is a host factor for RNA viruses including SARS-CoV-2

ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopa...

Identification of lectin receptors for conserved SARS-CoV-2 glycosylation sites

Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants

Periodic Reporting for period 2 - MAD-CoV 2 (Modern approaches for developing antivirals against SARS-CoV 2)